Akorn (AKRX) Announces FDA Okay for Ofloxacin Ophthalmic Solution USP
More News related to AKRX
- Akorn, Inc. (AKRX) Acquires Eli Lilly's (LLY) Capastat Sulfate
- Akorn Acquires Capastat(R) Sulfate from Eli Lilly and Company
- Akorn, Inc. (AKRX) Appoints Raj Rai as Interim Chief Executive Officer
- Akorn Announces Management Changes
- Akorn Reports First Quarter 2009 Financial Results
More News related to FDA
- Caraco Pharmaceutical Laboratories (CPD) Announces Its Reducing Its Workforce By 350 Employees
- Covidien (COV) Announces Health Canada Approval for its Generic Myocardial Perfusion Imaging Kit
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
Akorn, Inc. (NASDAQ: AKRX) announced that the FDA has granted approval for Akorn’s Abbreviated New Drug Application for Ofloxacin Ophthalmic Solution USP, 0.3%.
Ofloxacin Ophthalmic Solution is an anti-infective used to treat infections caused by bacteria in conjunctivitis and corneal ulcers. Annual sales for Ofloxacin were approximately $7.5 million in 2007, according to IMS sales data. [LJ]
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
